Shanghai‑based Excalipoint closed an oversubscribed $68.7 million seed financing to advance multiple T‑cell engager platforms targeting solid tumors, a headline funding round in China’s biotech scene. Investors include domestic and strategic healthcare funds; company founders said proceeds will support IND‑enabling studies and early clinical programs. Excalipoint described a multi‑platform strategy—TOPAbody, T‑Cell Immune Shield, TCE Probody—aimed at overcoming activation, tumor microenvironment and antigen‑targeting barriers in solid cancers. The raise underscores continued venture interest in bispecific and engager modalities despite the competitive landscape and safety challenges associated with T‑cell engaging therapies.